Abstract
Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson’s disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here, we identify PSMF1 as a new gene implicated in PD and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD and parkinsonism to perinatal lethality with neurological manifestations across 15 unrelated pedigrees with 22 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/PI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants impair mitochondrial membrane potential, dynamics and mitophagy in patient-derived fibroblasts. Additionally, we develop models of psmf1 knockdown Drosophila and Psmf1 conditional knockout mouse exhibiting age-dependent motor impairment, with diffuse gliosis in mice. These findings unequivocally link defective PSMF1 to early-onset PD and neurodegeneration and suggest mitochondrial dysfunction as a mechanistic contributor.
Competing Interest Statement
Pr.A.Le. acts as a paid consultant for Serna Bio. Mo.M.Ku. has received speaking and lecture fees by the International Parkinson and Movement Disorder Society, the World Parkinson Coalition, BIAL, Zambon, Esteve, Consulting for Elsevier Health Iberica, BIAL, UCB and Gondola Medical Technologies as well as funding grants from Research and Innovation Quiron Salud and EU Horizon 2023. Vi.Bo. has received research grants from the Stichting ParkinsonFonds, a research grant from Alzheimer Nederland and honoraria from Elsevier Ltd, for serving as co-Editor-in-Chief of Parkinsonism & Related Disorders. Ka.P.Ba. receives royalties from publication of the Oxford Specialist Handbook Parkinson's Disease and Other Movement Disorders (Oxford University Press, 2008), of Marsden's Book of Movement Disorders (Oxford University Press, 2012), and of Case Studies in Movement Disorders - Common and uncommon presentations (Cambridge University Press, 2017). Ka.P.Ba. has received honoraria/personal compensation for participating as consultant/scientific board member from Ipsen, Allergan, Merz and honoraria for speaking at meetings from Allergan, Ipsen, Merz, Sun Pharma, Teva, UCB Pharmaceuticals and from the American Academy of Neurology and the International Parkinson's Disease and Movement Disorders Society.
Funding Statement
For their work on this study: Fr.Ma. was supported by the Edmond J. Safra Fellowship in Movement Disorders, the Edmond J. Safra Movement Disorders Research Career Development Award (Grant ID: MJFF-023893), the American Parkinson Disease Association and the David Pearlman Charitable Foundation; Cr.Te. received funding from the program "Investissements d'avenir" ANR-10-IAIHU-06; Ai.Sa. was supported by La Caixa Postgraduate Abroad fellowship; Ba.Vo. was funded by the German Research Foundation DFG VO 2138/7-1 grant 469177153; No.Es. was supported by a Ramón y Cajal Fellowship RYC2021-034267-I and a research grant PID2022-137011OA-I00 funded by the Spanish Ministry of Science and the European Union; Pa.A.Le. was supported by a Royal Society Industry Fellowship (IF\R2\222002) with LifeArc technologies; St.Ef. was supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1'; Re.Bu. was supported by the German Academic Exchange Service (DAAD) as part of the German-Arab Transformation Program Line 4 (Project-ID 57166498); Gu.Co. was supported by the Global Parkinson's Genetics Program (GP2), which is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org; Grant ID: MJFF-024876); Ay.N.Ba. and Tu.Gü. were supported by Suna and İnan Kıraç Foundation and Koç; University School of Medicine, Istanbul, Turkey. Mi.Ze. received research support from the German Research Foundation (DFG 458949627; ZE 1213/2-1). Mi.Ze. acknowledges grant support by the European Joint Programme on Rare Diseases (EJP RD Joint Transnational Call 2022), and the German Federal Ministry of Education and Research (BMBF, Bonn, Germany), awarded to the project PreDYT (PREdictive biomarkers in DYsTonia, 01GM2302), by the Federal Ministry of Education and Research (BMBF) and the Free State of Bavaria under the Excellence Strategy of the Federal Government and the Länder, as well as by the Technical University of Munich - Institute for Advanced Study. Mi.Ze.'s research is also supported by a "Schlüsselprojekt" grant from the Else Kröner-Fresenius-Stiftung (2022_EKSE.185). Vi.Bo. received financial support from the Stichting Parkinson Fonds, The Netherlands, Grant. n. 1880. Part of this study (Br.Ch., An.Kw., Ma.Ch., Ea.Ng., Sz.Fa.) was supported by the Society for the Relief of Disabled Children (SRDC) and the Commissioned Paediatric Research at Hong Kong Children Hospital (PR-HKU-4) under the Health and Medical Research Fund (HMRF) by the Hong Kong Food and Health Bureau. This research was supported in part by the Intramural research Program of the NIH, National institute on Aging. Part of this work was supported by grants from the Cure Alzheimer's Fund and The Pershing Square Foundation to He.St. Su.Le. received grants from Fondation pour la Recherche Médicale (FRM, MND202004011718), la Fondation de France, France-Parkinson Association, la Fédération pour la Recherche sur le Cerveau (FRC) and the French program "Investissements d'avenir" (ANR-10-IAIHU-06). Cr.Te., Th.Co., Cl.Pi, Ma.Ca, Ba.A.Ha., Gu.Co., Su.Le. and Al.Br. were supported by the RMF through the project "DBS - From genetic mutations to motor circuit dysfunctions & recovery". He.Ho. was funded by the MRC (MR/S01165X/1, MR/S005021/1, G0601943, MR/V012177/1), The National Institute for Health Research, University College London Hospitals Biomedical Research Centre, Rosetrees Trust, Brain Research UK, Sparks GOSH Charity, the Rosetrees Trust PhD Plus award (PhD2022\100042) and Global Parkinson's Genetic Program (GP2; Grant ID: MJFF-022153).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individuals and/or their legal guardians recruited for this study gave informed consent for their participation. This study received approval from the NHS Health Research Autority (HRA) and Health and Care Research Wales (HCRW) (Integrated Research Approval System [IRAS] project ID 310045; Research Ethics Committee [REC] reference 22/NE/0080). Permission for inclusion of their anonymized medical data, including neuroimaging photographs, was obtained using standard forms at each local site by the responsible referring physicians.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵^ These Authors jointly supervised this work.
Data Availability
All data produced in the present study are contained in the manuscript and supplementary material or available upon reasonable request to the authors.
https://curtain.proteo.info/#/d12eee39-b848-45db-97e9-80e1ed23d4d2
https://curtain.proteo.info/#/96fc3542-f142-4314-b536-63b0ff2a6ebc
https://curtain.proteo.info/#/35fdd2ac-0a93-427d-bac0-a54a90a9d67e
https://curtain.proteo.info/#/393aec7f-1790-466a-abc2-23b8c91af443
